OTEZLA IMPROVES SKIN PLAQUES IN PSORIATIC ARTHRITIS PATIENTS WITH PSORIASIS1
Sustained improvement in skin symptoms up to 2 years1,a
aPALACE 3 study. Data as observed; includes all patients with baseline psoriasis BSA >3 who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24. Patients with BSA ≥3 at baseline: OTEZLA 30 mg BID, n = 92/167 (55.1%); placebo, n = 94/169 (55.6%).
- OTEZLA provided sustained improvement in skin symptoms for up to 4 years2
OTEZLA is also indicated for moderate to severe plaque psoriasis3
See the OTEZLA difference
Week 16 PASI-75 result
Individual results may vary.
*Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
BID, twice daily; BSA, body surface area; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy; PASI, Psoriasis Area and Severity Index.
- Edwards CJ, Blanco FJ, Crowley J, et al. Efficacy of Long-term (104-Week) Treatment With Apremilast in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-Label Extension. Presented at: the 74th Annual Meeting of the American Academy of Dermatology; March 4-8, 2016; Washington, DC.
- Edwards CJ, et al. Apremilast is associated with long-term (4-year) DAS-28 (CRP) remission and improvements in skin disease: results from a phase III study in DMARD/biologic-experienced patients with active psoriatic arthritis. Ann Rheum Dis. 2017;76 (suppl 2): Abstract FRI0487.
- OTEZLA Summary of Product Characteristics. Stockley Park, Uxbridge, UK: Celgene Europe, Ltd; 2017.